{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:59:03Z","timestamp":1789239543280,"version":"build-2803163510"},"reference-count":69,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T00:00:00Z","timestamp":1537833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"AstraZeneca Singapore Pte Ltd"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Obesity Reviews"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>With their novel, insulin\u2010independent mechanism, sodium\u2010glucose cotransporter\u20102 (SGLT2) inhibitors are a major turning point in the management of type 2 diabetes mellitus. At present, there are several SGLT2 inhibitors available or in development, and these oral anti\u2010hyperglycaemic agents lower plasma glucose through the inhibition of SGLT2\u2010mediated reuptake of filtered glucose in the kidney. This unique mechanism of action is also expected to result in other beneficial effects, such as weight loss and blood pressure reduction. In various studies, including randomized controlled trials and real\u2010world studies, patients treated with SGLT2 inhibitors have reported weight loss of around 1 to 3\u00a0kg. This review describes the characteristics of weight loss associated with SGLT2 inhibitor therapy, the clinical factors affecting SGLT2 inhibitor\u2010associated weight loss and the possible underlying mechanisms of SGLT2 inhibitor\u2010associated weight loss, including changes in metabolism and body composition, and the role of a reduction in insulin dose and compensatory hyperphagia. Understanding the weight loss effect of SGLT2 inhibitors, its related factors and underlying mechanisms can aid clinicians in optimal treatment decision\u2010making, provide valuable insight on both obesity and diabetes management and reveal areas of future research and new therapeutic options.<\/jats:p>","DOI":"10.1111\/obr.12755","type":"journal-article","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T20:24:29Z","timestamp":1537907069000},"page":"1630-1641","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":181,"title":["Weight loss associated with sodium\u2010glucose cotransporter\u20102 inhibition: a review of evidence and underlying mechanisms"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9446-2032","authenticated-orcid":false,"given":"P. C.","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Endocrinology Singapore General Hospital  Singapore"},{"name":"Duke\u2010NUS Medical School  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ganguly","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Singapore General Hospital  Singapore"},{"name":"Duke\u2010NUS Medical School  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.\u2010Y.","family":"Goh","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Singapore General Hospital  Singapore"},{"name":"Duke\u2010NUS Medical School  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12244"},{"key":"e_1_2_8_3_1","first-page":"199","article-title":"Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus","volume":"21","author":"Ribola FA","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-13-58"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1758-5996-7-S1-A58"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166125"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12625"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S112236"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004007"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22066"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009417"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12189"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.01.017"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3039-1"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2762"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2492w"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ15-0749"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8227(16)31022-1"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr3038w"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2017.0134"},{"key":"e_1_2_8_21_1","unstructured":"ShatskovA RezvaniG MansfieldT.Efficacy and safety of dapagliflozin in patients with type 2 diabetes: outcome by body mass index. Poster presented at the American Diabetic Association 76th Scientific Sessions 2016; New Orleans Louisiana USA; 10\u201314 June 2016."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/RMHP.S108586"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1055250"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12156"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12705"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2014.02.033"},{"key":"e_1_2_8_27_1","first-page":"670","article-title":"Cardio\u2010metabolic profile is influenced by modest modifications of body weight","volume":"8","author":"Pataky Z","year":"2012","journal-title":"Rev Med Suisse"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S129824"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01216.x"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-6-201203200-00003"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-3055"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.12.2948"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X115757"},{"key":"e_1_2_8_36_1","first-page":"186","article-title":"Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management","volume":"29","author":"Leiter LA","year":"2005","journal-title":"Can J Diabetes"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.06.017"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.356"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12403"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.10.025"},{"key":"e_1_2_8_41_1","doi-asserted-by":"crossref","unstructured":"FiorettoP on behalf of the DERIVE Investigators and Study Team.Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE study. Presented at: Endocrine Society's 100th Annual Meeting and Expo; March 19 2018; Chicago IL.","DOI":"10.1111\/dom.13413"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13206"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1693"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.251"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-12-RG-082"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01406.x"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1863"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0604"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.2337\/db15-1356"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/21623945.2017.1413516"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0832"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12644"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12187"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2012.59"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72227"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21653"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2018.02.002"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.2337\/db18-1163-P"},{"key":"e_1_2_8_59_1","unstructured":"SGLT\u20102 inhibitor empagliflozin effects on appetite and weight regulation. (SEESAW). Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02798744. Accessed 11 July 2018."},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12779"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12954"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2427"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30162-0"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1212914"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13077"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.113.060889"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4008-2"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0518"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13061"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.56.7196"}],"container-title":["Obesity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fobr.12755","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/obr.12755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T20:00:35Z","timestamp":1694808035000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/obr.12755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,25]]},"references-count":69,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1111\/obr.12755"],"URL":"https:\/\/doi.org\/10.1111\/obr.12755","archive":["Portico"],"relation":{},"ISSN":["1467-7881","1467-789X"],"issn-type":[{"value":"1467-7881","type":"print"},{"value":"1467-789X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,25]]},"assertion":[{"value":"2018-05-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}